Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has announced a webcast to present its second-quarter 2026 financial and operating results. The event is scheduled for Aug. 14, 2026, at 9 a.m. ET, with President and CEO Panna Sharma and other management team members reviewing the quarter ended June 30, 2026. The webcast will also include updates on upcoming milestones, clinical trials, and developments related to Lantern's proprietary RADR® platform and its Open-Medicine AI initiatives.
This announcement comes as Lantern Pharma continues to integrate AI and machine learning into cancer therapy development, a strategy that could significantly impact the oncology sector. The company's pipeline includes LP-184, an acylfulvene derivative being developed for multiple solid tumors, and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is currently being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. These programs highlight the company's focus on addressing unmet medical needs in oncology, potentially offering new hope for patients with difficult-to-treat cancers.
Beyond its clinical pipeline, Lantern Pharma has made strides in commercializing its AI capabilities. The company's withZeta.ai platform, a multi-agentic AI co-scientist, is now available as a subscription-based research tool for the global biomedical and drug development community. This move represents a new revenue stream and underscores the broader applicability of Lantern's AI technology beyond its own drug development efforts. By offering this platform commercially, Lantern is positioning itself at the forefront of AI-driven drug discovery, potentially accelerating research across the industry.
The webcast will be accessible via the investor relations section of Lantern Pharma's website, with a replay available after the event. For those interested in the full press release, additional details can be found at https://ibn.fm/l80kv. Lantern Pharma, headquartered in Dallas, Texas, also operates an AI Center of Excellence in Bengaluru, India, reflecting its global footprint in AI-driven healthcare innovation.
This upcoming webcast is a key opportunity for investors and industry observers to gain insights into Lantern Pharma's financial health and strategic direction. As the company continues to advance its clinical programs and expand its AI platform, the implications for precision oncology are substantial. The integration of AI in drug development could lead to more targeted and effective therapies, potentially transforming patient outcomes.
For ongoing updates and news regarding Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN. The company's commitment to leveraging AI in oncology is a testament to the growing role of technology in medicine, and its progress will be closely watched by the industry.
